GERNGeron Corp.

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...

Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Geron (NASDAQ:GERN) reported first-quarter 2026 net revenue of $61.8 million, up 31% year-over-year and 8% quarter-over-quarter, as the company continued to scale commercialization of Rytelo in the...

Geron (GERN) delivered earnings and revenue surprises of +60.00% and +2.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Geron (NASDAQ:GERN) Shares Pass Above 200 Day Moving Average - Here's What Happened...

Sweden Will Consider Ways To Limit Energy Use If Iran War Continues, Government Says Authored by Victoria Friedman via The Epoch Times (emphasis ours), Sweden may need to consider options to reduce energy consumption, including rationing, if the disruption to the flow of fuel supplies...

Geron (NASDAQ:GERN) Shares Down 5.1% - Here's What Happened...

Geron Corporation (NASDAQ:GERN - Get Free Report) has been assigned an average rating of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assign...

Geron (NASDAQ:GERN) executives used a presentation at the Needham Healthcare Conference to outline the company's early commercial trajectory for its telomerase inhibitor imetelstat (marketed as...